A5026179323- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Monoclonal and Polyclonal Antibodies Research
- Breast Lesions and Carcinomas
- PI3K/AKT/mTOR signaling in cancer
- 3D Printing in Biomedical Research
- MicroRNA in disease regulation
- Lung Cancer Treatments and Mutations
- Tissue Engineering and Regenerative Medicine
- Cancer-related Molecular Pathways
- Cancer Risks and Factors
- Colorectal Cancer Treatments and Studies
- Fibroblast Growth Factor Research
- Gene expression and cancer classification
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Radiopharmaceutical Chemistry and Applications
- Epigenetics and DNA Methylation
- Cancer Diagnosis and Treatment
Hospital Clínico Universitario de Valencia
2015-2025
Centro de Investigación Biomédica en Red de Cáncer
2017-2025
INCLIVA Health Research Institute
2016-2025
Universitat de València
2016-2025
Centre for Biomedical Network Research on Rare Diseases
2018-2025
Biomedical Research Institute
2013-2024
Weatherford College
2024
GEICAM – Spanish Breast Cancer Group
2011-2023
Instituto de Salud Carlos III
2017-2022
Centro de Investigación Biomédica en Red
2015-2020
Purpose This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus alone in patients with human epidermal growth factor receptor 2 (HER2) –positive metastatic breast cancer (MBC). Patients and Methods were randomly assigned to six cycles of 100 mg/m every 3 weeks, or without 4 mg/kg loading dose followed by weekly until disease progression. Results A total 186 received at least one the study drug. Trastuzumab was significantly superior terms overall response...
Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectroscopy-based sequencing and reverse-phase protein arrays to 547 human breast cancers 41 cell lines, we determined the subtype specificity signaling effects of PIK3CA, AKT, PTEN mutations PIK3CA on responsiveness PI3K inhibition vitro outcome after adjuvant tamoxifen. were more hormone receptor-positive (34.5%) HER2-positive (22.7%) than basal-like tumors (8.3%). AKT1 (1.4%) (2.3%)...
Metaplastic breast cancers (MBC) are aggressive, chemoresistant tumors characterized by lineage plasticity. To advance understanding of their pathogenesis and relatedness to other cancer subtypes, 28 MBCs were compared with common using comparative genomic hybridization, transcriptional profiling, reverse-phase protein arrays sequencing for mutations. showed unique DNA copy number aberrations cancers. PIK3CA mutations detected in 9 19 (47.4%) versus 80 232 hormone receptor-positive (34.5%; P...
Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical molecular features HER2-low BC yet to be elucidated. Here, we collected retrospective clinicopathological PAM50 data from 3,689 patients disease made following observations. First, proportion was higher HR-positive (65.4%) than triple-negative (TNBC, 36.6%). Second, within disease, luminal-related...
To evaluate the antitumor activity and pharmacodynamic/biologic effect of gefitinib 500 mg/day monotherapy in patients with previously treated, advanced breast cancer.In this phase II multicenter trial, primary objective was assessment tumor response rate gefitinib; secondary objectives included analysis pharmacodynamic biologic profiles healthy tissue.while phosphorylation mitogen-activated protein kinase inhibited both tissues, treatment induced p27 a decrease Ki67 skin but not tumors....
The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) 50% patients with human epidermal growth factor receptor 2 (HER2) -positive breast cancer whose disease progressed during prior trastuzumab-based therapy. To define whether this previously observed encouraging activity was result the or alone, we recruited third cohort who received without trastuzumab. We then investigated impact reintroducing to on monotherapy.Twenty-nine HER2-positive therapy (840 mg...
Abstract Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary tissues from patients. Intrinsic subtype was identified using a PAM50 classifier χ2 tests determined the differences variable distribution. The rate conversion 0% basal-like tumors, 23.1% HER2-enriched (HER2-E) 30.0% luminal B 55.3% A tumors. 40.2% cases, tumors converted...
Triple negative breast cancer (TNBC) is a heterogeneous disease with distinct molecular subtypes that differentially respond to chemotherapy and targeted agents. The purpose of this study explore the clinical relevance Lehmann TNBC by identifying any differences in response neoadjuvant among them. We determined gene expression profiling paraffined pre-treatment tumor biopsies from 125 patients treated anthracyclines and/or taxanes +/- carboplatin. explored clinicopathological characteristics...
Purpose Ixabepilone (BMS-247550) is an epothilone analog that optimizes the properties of naturally occurring B. Natural epothilones and their analogs promote tumor cell death by binding to tubulin stabilizing microtubules, causing apoptosis. This international phase II trial assessed activity ixabepilone in patients with metastatic breast cancer (MBC) was resistant taxane therapy. Patients Methods MBC patients, who had experienced disease progression while receiving or within 4 months...
Accumulating evidence suggests that both levels and activity of the estrogen receptor (ER) progesterone (PR) are dramatically influenced by growth-factor (GFR) signaling pathways, this crosstalk is a major determinant breast cancer progression response to therapy. The phosphatidylinositol 3-kinase (PI3K) pathway, key mediator GFR signaling, one most altered pathways in cancer. We thus examined whether deregulated PI3K luminal ER+ tumors associated with ER level intrinsic molecular subtype....
Taxanes are among the most active drugs for treatment of metastatic breast cancer, and, as a consequence, they have also been studied in adjuvant setting. After cancer surgery, women with lymph node–positive disease were randomly assigned to fluorouracil, epirubicin, and cyclophosphamide (FEC) or FEC followed by weekly paclitaxel (FEC-P). The primary endpoint study—5-year disease-free survival (DFS)—was assessed Kaplan–Meier analysis. Secondary endpoints included overall analysis prognostic...
To evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and compare this combination with same given as primary systemic (neoadjuvant) therapy.A total 1,355 women operable breast cancer were randomly assigned one three treatments: surgery followed by doxorubicin (75 mg/m(2)) cyclophosphamide, methotrexate, fluorouracil (CMF; arm A); (200 plus (60 mg/m(2)), CMF (arm B); or C). The two coprimary objectives assess effects on relapse-free survival (RFS) postoperative...
Abstract The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary matched metastatic breast tumors as could influence patient management. Paraffin sections 50 μm were used for DNA extraction slides 3 immunohistochemistry (IHC) FISH. Estrogen receptor, progesterone HER2 IHC repeated a central laboratory both metastases. levels assessed by phosphoinositide 3-kinase (PI3K) pathway mutations detected mass...
Abstract Background: The HER-2 receptor undergoes a proteolytic cleavage generating an NH2-terminally truncated fragment, p95HER-2, that is membrane-associated and tyrosine-phosphorylated. We have reported but not the full-length receptor, p185HER-2, correlated with extent of lymph node involvement in patients breast cancer its expression was significantly enhanced nodal metastatic tissue. These facts suggested important role for p95HER-2 either as marker or cause metastasis poor outcome...